bpi glp-1 Labs to Stop Compounding GLP-1s | Sabina Hemmi posted on the topic and intra BPI Labs | 503B Compounding

Description

These insights reveal whether your biology is optimized for GLP-1 receptor activation or dopamine-pathway sensitivity, allowing your clinician to select the medication class most likely to deliver results for your unique genetic profile

The UK medicines regulator, the MHRA, has updated the product information for healthcare professionals and patients regarding the "small risk of severe acute pancreatitis in patients taking GLP-1s." While rare, the sheer scale of GLP-1 use in the UK with one recent study suggesting 1.6 million adults had used them in the last 12 months, and 3.3 million were interested in trying them in the following year makes it important for clinicians and patients to be aware of the warning signs of pancreatitis, said the regulator